Business Context and Reporting Period
Prelude Therapeutics Inc. (PRLD) is a precision oncology company focused on developing novel cancer medicines. This Form 10-Q covers the quarterly period ended March 31, 2026. The company operates as a single segment and is classified as a smaller reporting company. As of the filing date, the company had an accumulated deficit of $693.4 million and continues to rely on external financing and collaboration agreements to fund operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $4.6 million | $0 |
| Net Loss | $(10.4) million | $(32.1) million |
| Net Loss Per Share (Basic/Diluted) | $(0.13) | $(0.42) |
| Operating Expenses | $18.8 million | $34.6 million |
| Cash Used in Operating Activities | $(21.7) million | $(34.2) million |
| Cash, Cash Equivalents, and Marketable Securities | $84.8 million | $103.2 million (approx.) |
| Total Assets | $119.6 million | $141.3 million (Dec 31, 2025) |
Note: Revenue in Q1 2026 is derived from collaboration agreements, not product sales. The company has no product revenue to date.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $4.6 million in revenue in Q1 2026, compared to zero in Q1 2025. This revenue stems from an Exclusive Option Agreement with Incyte Corporation entered in November 2025, recognized over time as performance obligations are satisfied.
- Expense Reduction: Total operating expenses decreased by $15.8 million (46%) year-over-year. Research and Development (R&D) expenses dropped significantly from $28.8 million to $13.6 million, primarily due to the pause in clinical development of the SMARCA2 degrader program in late 2025 and reduced stock-based compensation.
- Net Loss Improvement: Net loss narrowed by $21.7 million to $10.4 million, driven by the reduction in operating costs and increased other income (interest and tax credits).
- Liquidity Position: Cash and marketable securities decreased by approximately $18.4 million from the prior year-end balance, reflecting operating cash burn, though the company maintains a liquidity position of $84.8 million as of March 31, 2026.
Guidance, Outlook, and Risks
- Capital Raise (Subsequent Event): In April 2026, subsequent to the period end, the company completed an offering of common stock and pre-funded warrants, generating gross proceeds of approximately $90.0 million. Management estimates these funds will support operations for at least the next twelve months.
- Pipeline Progress:
- JAK2 V617F: Lead candidate PRT12396 received FDA IND clearance in February 2026; Phase 1 enrollment has commenced.
- KAT6A: Lead candidate PRT13722 is on track for an IND filing in mid-2026, with Phase 1 initiation anticipated in the second half of 2026.
- SMARCA2: Clinical development paused in Q4 2025 to prioritize other programs.
- Risks and Contingencies:
- The company has no approved products and expects to incur losses for the foreseeable future.
- Continued dependence on equity financing, debt, or strategic collaborations to fund operations.
- Uncertainty regarding the successful completion of clinical trials and regulatory approvals.
- Reliance on key personnel and protection of proprietary technology.
Investor Verification Checklist
- Runway Validation: Verify the sufficiency of the $90 million April 2026 proceeds against the company's projected burn rate for the next 12 months.
- Revenue Sustainability: Confirm the timeline for recognizing the remaining $28.0 million in deferred revenue from the Incyte agreement and the likelihood of Incyte exercising the $100 million option.
- Clinical Milestones: Monitor the initiation of the Phase 1 trial for PRT12396 and the IND filing status for PRT13722 in mid-2026.
- Expense Management: Assess whether the reduced R&D spend (due to paused programs) is sustainable or if costs will rebound as new programs advance.
- Dilution Risk: Review the terms of the April 2026 offering and the remaining capacity under the $400 million shelf registration statement.